Skip to main content
BrainCited

Acetyl-L-Carnitine para Age-Related Cognitive Decline

C

Mixed results in healthy adults but more consistently positive outcomes in elderly populations with existing cognitive concerns. Used as a prescription drug in some European countries for cognitive impairment.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'ingredient\u003Dacetyl\u002Dl\u002Dcarnitine\u0026condition\u003Dcognitive\u002Ddecline'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

Conclusión

Mixed results in healthy adults but more consistently positive outcomes in elderly populations with existing cognitive concerns. Used as a prescription drug in some European countries for cognitive impairment.

Key Study Findings

Randomized Controlled Trial
Comparative study of choline alfoscerate as a combination therapy with donepezil: A mixed double-blind randomized …
Dose: None vs: None Outcome: Cognitive decline Efecto: None None

Población: Alzheimer's disease patients

Systematic Review
Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update.
Dose: None vs: None Outcome: None Efecto: None None

Población: None

Review
Chronic pain and adult hippocampal neurogenesis: translational implications from preclinical studies.
Dose: None vs: None Outcome: None Efecto: None None

Población: Chronic pain patients (preclinical review)

Review
Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, & circadian dysfunction in Parkinson's disease. An integrated strategy …
Dose: None vs: None Outcome: None Efecto: None None

Población: Parkinson's disease patients

Controlled Clinical Trial
Effect of mitochondrial cofactors and antioxidants supplementation on cognition in the aged canine.
Dose: mitochondrial cofactors + antioxidants vs: control diet Outcome: cognitive function in aged dogs Efecto: improved learning and memory None

Población: Aged beagle dogs

Randomized Controlled Trial n=106 Double-blind
A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in …
Dose: None vs: placebo Outcome: None Efecto: None p = 0.0083

Población: Alzheimer's disease patients

Key Statistics

14

Estudios

1000

Participantes

Positive

C

Calificación

Referenced Papers

The Cochrane database … 2003 94 citas

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosificaciones de uso común

general:
500-2,000 mg/day
cognitivesupport:
1,500-3,000 mg/day

Límite superior: Well-tolerated up to 3,000 mg/day

Dosificaciones estudiadas en la investigación

Dosificación Duración Efecto N
None -- Positive --
None -- Positive --
None -- Mixed --
None -- Mixed --
mitochondrial cofactors + antioxidants -- Positive --
None -- Positive 106
None -- Positive 427
None 8.0 weeks Positive --

Mejor momento para tomar: Morning, on empty stomach or with meals

Safety & Side Effects

Efectos secundarios reportados

  • Gastrointestinal discomfort (nausea, vomiting, diarrhea)
  • Fishy body odor
  • Restlessness or insomnia
  • Increased appetite

Interacciones conocidas

  • Anticoagulants (may increase bleeding risk)
  • Thyroid medications (may enhance thyroid hormone effects)
  • AZT (antiretroviral — may reduce neuropathy)

Ingesta máxima tolerable: Well-tolerated up to 3,000 mg/day

Consulte siempre a su profesional de salud antes de comenzar cualquier suplemento.Siempre consulte a su profesional de salud antes de comenzar cualquier suplemento.

Frequently Asked Questions

Does Acetyl-L-Carnitine help with Age-Related Cognitive Decline?
Based on 14 studies with 1,000 participants, there is limited but promising evidence that Acetyl-L-Carnitine may support Age-Related Cognitive Decline management. Our evidence grade is C (Some Evidence).
How much Acetyl-L-Carnitine should I take for Age-Related Cognitive Decline?
Studies have used various dosages. A commonly studied range is 500-2,000 mg/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Acetyl-L-Carnitine?
Reported side effects may include Gastrointestinal discomfort (nausea, vomiting, diarrhea), Fishy body odor, Restlessness or insomnia, Increased appetite. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Acetyl-L-Carnitine and Age-Related Cognitive Decline?
We rate the evidence as Grade C (Some Evidence). This rating is based on 14 peer-reviewed studies with 1,000 total participants. The overall direction of effect is positive.

Related Evidence

Aviso legal FDA: Estas declaraciones no han sido evaluadas por la Food and Drug Administration. Los productos y la información en este sitio web no están destinados a diagnosticar, tratar, curar ni prevenir ninguna enfermedad. Las calificaciones de evidencia presentadas se basan en nuestro análisis de investigación publicada revisada por pares y no constituyen consejo médico. Siempre consulte a su profesional de salud antes de comenzar cualquier régimen de suplementos.